Following U.S. Stocks are among the “Most Active” Stocks in the course of recent trading session, Monday: Apple Inc (NASDAQ:AAPL), Bank of America Corp (NYSE:BAC), Salix Pharmaceuticals, Ltd (NASDAQ:SLXP), Intel Corporation (NASDAQ:INTC)

• Apple Inc (NASDAQ:AAPL), with shares gain 0.43% is now trading at $124.18. The Stock is active as 10.91M shares changed hands versus its average volume of 59.79M shares.

• Bank of America Corp (NYSE:BAC), with shares dwindled -0.25% is now trading at $16.05. The Stock is active as 15.18M shares changed hands versus its average volume of 97.25M shares.

• Salix Pharmaceuticals, Ltd (NASDAQ:SLXP) with shares enhanced 1.95% is now trading at $172.70. The Stock is active as 7.99M shares changed hands versus its average volume of 4.58M shares.

• Intel Corporation (NASDAQ:INTC), with shares dipped -0.57% is now trading at $30.75. The Stock is active as 8.20M shares changed hands versus its average volume of 30.43M shares.

Latest NEWS regarding these Stocks are depicted underneath:

Bank of America Corporation (NYSE:BAC)

On March 11, Bank of America Corporation (BAC), declared that the corporation’s Board of Directors authorized a $4 billion ordinary stock repurchase program.

The Federal Reserve Board (Fed) has informed the corporation that it accomplished its 2015 Comprehensive Capital Analysis and Review and it did not object to the corporation’s capital plan for the period from the second quarter of 2015 through the second quarter of 2016. This plan comprises the $4 billion stock repurchase program and maintaining the ordinary stock dividend at the current rate of $0.05 per share per quarter. The Fed also asked Bank of America to submit an additional capital plan by September 30, 2015 addressing certain weaknesses identified in the corporation’s capital planning process. If Bank of America does not make material progress in addressing these key weaknesses, the Fed may restrict the corporation’s capital distributions.

“Over the last few years, we have simplified the corporation, sharpened our focus on serving customers and we are returning capital to our shareholders,” said Chief Executive Officer Brian Moynihan. “We believe that this year’s planned repurchase program is the best way to continue to drive value for our shareholders. We are committed to meeting the requirements in the time frame the Fed has established.”

Bank of America Corporation, through its auxiliaries, provides banking and financial products and services for individual consumers, small and middle market businesses, institutional investors, large corporations, and governments worldwide.

Apple Inc. (NASDAQ:AAPL)

As Amazon.com dropped down from the top spot last year to No. 3, Apple Inc. (AAPL), the maker of Macs, iPhones and iPads, which was ranked third last year, reclaimed the status as the No. 1 brand among small to mid-sized businesses.

Southwest Airlines, which was No. 5 last year, finished second this year. Google dropped down from second to fourth.

The results are highlighted in the 13th annual SMB Insights Study from The Business Journals, which surveyed more than 1,600 SMB owners and top administration decision makers. Companies were ranked based on several criteria, counting industry leadership, vision, ethical behavior, general popularity, good pricing, and customer service.

In addition to brand equity ratings, this year’s survey also comprised of purchasing dynamics within the SMB market, plus it comprised of 15 product categories. For the first time, the study noted key drivers behind brand switching and decision-making timeframes.

Apple Inc. designs, manufactures, and markets mobile communication and media devices, personal computers, and portable digital music players worldwide.

Salix Pharmaceuticals Ltd. (NASDAQ:SLXP)

Today, Valeant Pharmaceuticals International, Inc. (VRX) and Salix Pharmaceuticals, Ltd. (SLXP) declared that they have reached an amendment to their Contract and Plan of Merger, dated February 20, 2015. Following the amendment, Valeant raised the offer price to attain all the outstanding ordinary stock of Salix from $158.00 per share to $173.00 per share in cash, or a total enterprise value of about $15.8 billion, through April 7, 2015. The revised offer price of $173.00 per share provides an additional about $1 billion in cash consideration to Salix stockholders, and represents an raise of 9.49% and 43.9%, respectively, over the original offer price of $158.00 per share and the unaffected price of Salix ordinary stock on January 16, 2015, of $120.19. As formerly declared, if the minimum tender condition is satisfied at the end of the day on March 31, 2015, Valeant anticipates to close the transaction on April 1, 2015. If all of the conditions to the tender offer have not been satisfied by April 8, 2015, the offer price will drop back to $158.00 per share. In consideration for the raise of the offer price through April 7, 2015, the termination fee payable by Salix to Valeant has been raised by $100 million and the outside date after which either party may terminate the transaction has been moved from August 20, 2015, to May 1, 2015. The amendment was approved by the Boards of Directors of both companies.

The offer documents and Salix’s solicitation/recommendation statement on Plan 14D-9 will be amended to reflect the amended terms.

Sullivan & Cromwell LLP served as Valeant’s legal counsel, and Salix was advised by Cadwalader Wickersham & Taft LLP. Deutsche Bank and HSBC Securities (USA) Inc. acted as financial advisors to Valeant. Centerview Partners and J.P. Morgan acted as financial advisors to Salix.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) is a multinational specialty pharmaceutical corporation that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics.

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products and medical devices for the prevention and treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and commercialize them through the Corporation’s 500-member specialty sales force. Salix trades on the NASDAQ Global Select Market under the ticker symbol “SLXP”.

Intel Corporation (NASDAQ:INTC)

Intel Corporation (INTC), and IDC lowered their 2015 PC outlook. Intel lowered its March quarter outlook, blaming “the change in proceed outlook” on “weaker than predictable demand for business desktop PCs”, while computer hardware market research firm IDC issued a press release, lowering its 2015 full-year outlook for PC shipments from 3.3% decline to 4.9% fall, citing weaknesses in emerging markets, due to “continued political instability, commodity pricing pressures, and currency devaluations in these regions.”

Intel Corporation designs, manufactures, and sells integrated digital technology platforms worldwide. It operates through PC Client Group, Data Center Group, Internet of Things Group, Mobile and Communications Group, Software and Services, and All Other segments.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.